

Bipolar Disorder Therapeutics Market to Reach USD 10,970M by 2035 | Fact.MR Report

Analysis of Bipolar Disorder Therapeutics Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries

ROCKVILLE, MD, UNITED STATES, June 12, 2025 /EINPresswire.com/ -- In 2025, the [Bipolar Disorder Therapeutics Market](#) is expected to reach USD 7,860 million. According to Fact.MR's estimate, the valuation is expected to increase at a compound annual growth rate (CAGR) of 3.4%, reaching USD

10,970 million by 2035. The increasing frequency of bipolar spectrum illnesses worldwide, advancements in diagnostic technologies, and the growing need for long-term, specialized mental health management solutions are the main factors driving the industry's growth.



For More Insights into the Market, Request a Sample of this Report:

https://www.factmr.com/connectus/sample?flag=S&rep_id=7280

Market Drivers: Rising Prevalence and Awareness

The increasing prevalence of bipolar disorder is a primary driver of market growth. Factors such as high-stress environments, changing lifestyles, and substance abuse are contributing to the global rise in bipolar disorder cases. According to Fact.MR, the lifetime prevalence of bipolar disorder is approximately 1%, with a one-year prevalence of about 0.5% worldwide. This growing caseload, combined with early onset in teenagers and improved diagnostic tools, is fueling demand for bipolar disorder therapeutics.

Technological Advancements and New Drug Approvals

The bipolar disorder therapeutics market is undergoing a transformation driven by advancements in pharmacotherapy and digital health solutions. Recent innovations include the development of long-acting injectable (LAI) antipsychotics, such as aripiprazole and risperidone,

which improve patient adherence by reducing the frequency of dosing. For example, in September 2022, Otsuka America Pharmaceutical, Inc. and H. Lundbeck A/S received FDA approval for a two-month, ready-to-use aripiprazole injectable for bipolar I disorder and schizophrenia, enhancing treatment outcomes.

Mood stabilizers, such as lithium, valproate, and lamotrigine, remain a cornerstone of bipolar disorder treatment, dominating the market with a 35% share in 2023. These drugs are favored for their ability to manage mood swings and stabilize patients' mental and emotional states. Additionally, atypical antipsychotics like lumateperone (Caplyta) and cariprazine (Vraylar) are gaining traction due to their improved efficacy and reduced side effects. In April 2022, the FDA approved lumateperone for bipolar depression, marking a significant milestone in addressing depressive episodes.

Digital therapeutics and mobile health platforms are also reshaping the market. Wearable devices and mobile applications, such as Pear Therapeutics' reSET-O, enable real-time mood tracking and remote consultations, improving patient engagement and adherence. These technologies are particularly impactful in underserved areas, where access to mental health professionals is limited.

Regional Insights: North America and Europe Lead

North America held a dominant 40% market share in 2024, driven by high prevalence rates, advanced healthcare infrastructure, and robust mental health initiatives. The National Institute of Mental Health estimates that 4.4% of U.S. adults live with bipolar disorder, creating significant demand for therapeutics. The U.S. government's Mental Health Parity and Addiction Equity Act (MHPAEA) ensures equitable access to mental health treatments, further supporting market growth.

Europe accounted for over 30% of the global market in 2024, with Germany, France, and Italy leading due to well-developed healthcare systems and increasing mental health investments. Germany's bipolar disorder therapeutics market is projected to grow at a CAGR of 2.6% through 2026, driven by rising awareness and supportive government policies. The Asia-Pacific region, with a 23% market share in 2024, is expected to grow at a CAGR of 5.5% through 2031, fueled by improving healthcare access and growing mental health awareness in countries like China and India.

Get Customization on this Report for Specific Research Solutions:

https://www.factmr.com/connectus/sample?flag=S&rep_id=7280

Market Segmentation: Mood Stabilizers and Antipsychotics

The bipolar disorder therapeutics market is segmented by drug class, including mood stabilizers, antipsychotics, antidepressants, and others. Mood stabilizers lead due to their effectiveness in

managing both manic and depressive episodes. Antipsychotics, particularly atypical antipsychotics, are expected to see significant growth due to innovations like long-acting injectables and their ability to address complex symptoms with fewer cognitive side effects.

By mechanism of action, selective serotonin reuptake inhibitors (SSRIs) held a 25.45% market share in 2023, driven by their role in managing depressive episodes. Long-acting injectables and combination therapies are gaining popularity for their ability to improve adherence, addressing the 40–50% non-adherence rate among bipolar disorder patients.

Competitive Landscape: Innovation and Strategic Partnerships

The market is highly competitive, with key players such as Pfizer Inc., Otsuka Holdings Co., Ltd., AstraZeneca plc, Eli Lilly and Company, and Bristol-Myers Squibb leading through innovation and strategic acquisitions. In December 2023, Bristol-Myers Squibb acquired Karuna Therapeutics, strengthening its neuroscience portfolio with novel psychiatric treatments. Similarly, Eli Lilly's March 2024 commitment to developing safer mood stabilizers underscores the industry's focus on addressing unmet needs.

Companies are also investing in personalized medicine, leveraging genetic profiling and AI-driven drug development to tailor treatments to individual patient needs. These advancements aim to improve efficacy and reduce side effects, a critical concern given that adverse effects like weight gain and metabolic disorders often lead to poor medication adherence.

Challenges and Opportunities

Despite its growth, the market faces challenges, including side effects of long-term medication use and disparities in mental healthcare access, particularly in low-income regions. Misdiagnosis and stigma surrounding mental health also hinder timely treatment. However, opportunities abound in emerging markets like Asia-Pacific, where healthcare infrastructure is improving, and in the development of novel therapies, such as glutamatergic modulators and anti-inflammatory compounds.

In the short term (2024–2026), the market will benefit from new drug approvals and digital health integration. In the medium term (2026–2030), personalized medicine and AI-driven diagnostics will drive growth. In the long term (2030–2034)

Future Outlook: A Promising Trajectory

The bipolar disorder therapeutics market is poised for steady growth, with a projected value of US\$ 6.8 billion by 2026. Rising awareness, technological advancements, and a focus on patient-centric care will continue to drive demand. As pharmaceutical companies innovate and governments expand mental health initiatives, the market is set to deliver improved outcomes for millions living with bipolar disorder.

Check out More Related Studies Published by Fact.MR:

[Peptide-based cancer therapeutics market](#) is forecasted to increase from a valuation of US\$ 10.1 billion in 2023 to US\$ 21.4 billion by the end of 2033

[Peptide-based Infection Therapeutics Market](#) is forecasted to increase at a high CAGR of 8.3% over the next ten years.

S. N. Jha

Fact.MR

+1 628-251-1583

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/821452926>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.